Meta-analysis Of The Efficacy Of GLP-1 Receptor Agonist Liraglutide In The Treatment Of Patients With Type 2 Diabetes Combined With Non-alcoholic Fatty Liver Disease

Objective: A meta-analysis was performed to systematically evaluate the efficacy of liraglutide in patients with type 2 diabetes combined with non-alcoholic fatty liver disease.Methods: Databases included Pub Med,the Cochrane Library,EMbase,China National Knowledge Infrastructure(CNKI),VIP database(VIP),Wanfang database were searched to find randomized controlled trials of liraglutide for the treatment of patients with type 2 diabetes combined with non-alcoholic fatty liver disease.The search time was from the establishment of the database to October 2019.Meta-analysis were performed using Rev Man 5.3 software.The mean difference(MD)or the standardized mean difference(SMD)were used to analyze the continuous variables.Random effect model method or fixed effect model was used for data analysis according to Heterogeneity test.The quality of the included literatures was evaluated and the heterogeneity of the results was analyzed.Results: Eight randomized controlled trials were included in this meta-analysis.A total of 546 patients were analyzed,including 244 patients in the liraglutide group and 302 patients in the control group(other drugs group).The data after liraglutide or other drugs treatment was included and analyzed.The meta-analysis showed that the Hb A1c(MD:-0.10,95% CI:-0.14～-0.07,P<0.00001),HOMA-IR(MD:-0.77,95% CI:-1.14～-0.40,P<0.0001),LDL(MD:-0.31,95% CI:-0.54～-0.08,P=0.008),TG(MD:-0.56,95% CI:-0.74～-0.39,P<0.00001)of liraglutide group were significantly lower than those in the control group.However,there was no significant difference in the HDL(MD:0.06,95% CI:-0.07～0.18,P=0.37),AST(SMD:-0.67,95% CI:-1.74～0.39,P=0.21),ALT(SMD:-1.44,95% CI:-2.87～-0.01,P=0.05)between the liraglutide group and the control group.BMI(MD:-1.55,95% CI:-2.89～-0.21,P=0.02)and the liver fat content(SMD:-1.16,95% CI:-1.81 ～-0.51,P = 0.0005)of liraglutide group were significantly lower than those in the control group.Conclusion: GLP-1 receptor agonist liraglutide not only ameliorate carbohydrates and lipid metabolism,alleviate insulin resistance,but also reduce the weight and liver fat content.Liraglutide is a good medicine in the treatment of patients with T2 DM combined with NAFLD.